BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11237676)

  • 1. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.
    Bolon B; Carter C; Daris M; Morony S; Capparelli C; Hsieh A; Mao M; Kostenuik P; Dunstan CR; Lacey DL; Sheng JZ
    Mol Ther; 2001 Feb; 3(2):197-205. PubMed ID: 11237676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
    Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
    Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biglycan deficiency interferes with ovariectomy-induced bone loss.
    Nielsen KL; Allen MR; Bloomfield SA; Andersen TL; Chen XD; Poulsen HS; Young MF; Heegaard AM
    J Bone Miner Res; 2003 Dec; 18(12):2152-8. PubMed ID: 14672350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin gene-modified BMSCs with hydroxyapatite scaffold for treating critical-sized mandibular defects in ovariectomized osteoporotic rats.
    Liu X; Bao C; Xu HHK; Pan J; Hu J; Wang P; Luo E
    Acta Biomater; 2016 Sep; 42():378-388. PubMed ID: 27318268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
    Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
    Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function.
    Shimizu-Ishiura M; Kawana F; Sasaki T
    J Electron Microsc (Tokyo); 2002; 51(5):315-25. PubMed ID: 12455916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.
    Lloyd SA; Morony SE; Ferguson VL; Simske SJ; Stodieck LS; Warmington KS; Livingston EW; Lacey DL; Kostenuik PJ; Bateman TA
    Bone; 2015 Dec; 81():562-572. PubMed ID: 26318907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model.
    Yang SY; Mayton L; Wu B; Goater JJ; Schwarz EM; Wooley PH
    Arthritis Rheum; 2002 Sep; 46(9):2514-23. PubMed ID: 12355500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
    Lamoureux F; Richard P; Wittrant Y; Battaglia S; Pilet P; Trichet V; Blanchard F; Gouin F; Pitard B; Heymann D; Redini F
    Cancer Res; 2007 Aug; 67(15):7308-18. PubMed ID: 17671200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.
    Rubin J; Ackert-Bicknell CL; Zhu L; Fan X; Murphy TC; Nanes MS; Marcus R; Holloway L; Beamer WG; Rosen CJ
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4273-9. PubMed ID: 12213884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
    Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
    J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
    Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
    Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
    Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
    Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
    Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
    Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties.
    Ulrich-Vinther M; Schwarz EM; Pedersen FS; Søballe K; Andreassen TT
    Bone; 2005 Dec; 37(6):751-8. PubMed ID: 16169783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
    Simonet WS; Lacey DL; Dunstan CR; Kelley M; Chang MS; Lüthy R; Nguyen HQ; Wooden S; Bennett L; Boone T; Shimamoto G; DeRose M; Elliott R; Colombero A; Tan HL; Trail G; Sullivan J; Davy E; Bucay N; Renshaw-Gegg L; Hughes TM; Hill D; Pattison W; Campbell P; Sander S; Van G; Tarpley J; Derby P; Lee R; Boyle WJ
    Cell; 1997 Apr; 89(2):309-19. PubMed ID: 9108485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice.
    Kim D; Cho SW; Her SJ; Yang JY; Kim SW; Kim SY; Shin CS
    Stem Cells; 2006 Jul; 24(7):1798-805. PubMed ID: 16556708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.
    Valenta A; Roschger P; Fratzl-Zelman N; Kostenuik PJ; Dunstan CR; Fratzl P; Klaushofer K
    Bone; 2005 Jul; 37(1):87-95. PubMed ID: 15869920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.